Clinical Trials
86 trialsFirst in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
PIKALO-1
Eli Lilly and Company
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
DESCENT-1
A2 Biotherapeutics Inc.
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono
OP-NEU-101
Onchilles Pharma Inc
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
MK-2870-001
Klus Pharma Inc.
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NantBioScience, Inc.
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Vanderbilt-Ingram Cancer Center
ELUCIDATE
Exscientia AI Limited
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Exscientia AI Limited
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
ARC-25
Arcus Biosciences, Inc.
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
BetaBart
Radiopharm Theranostics, Ltd
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
MK-4700-001
Merck Sharp & Dohme LLC
PNeoVCA
Mayo Clinic
SMP-3124LP in Adults With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
DUNP19
Radiopharm Theranostics, Ltd
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
GUARDIAN-101
Clasp Therapeutics, Inc.
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Normunity AccelCo, Inc.
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Poseida Therapeutics, Inc.
VISTA
Baylor College of Medicine
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
FORTITUDE-301
Amgen
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
POTENTIATE
Boundless Bio, Inc.
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.